
PharmaCyte Biotech Sets 1-for-19 Reverse Stock Split, Effective Nov. 12
Split-adjusted trading began Nov. 13 under the unchanged ticker PMCB, with a new CUSIP of 71715X302.
PharmaCyte Biotech, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

Split-adjusted trading began Nov. 13 under the unchanged ticker PMCB, with a new CUSIP of 71715X302.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Entry into a material definitive agreement · Completion of acquisition or disposition of assets · Financial statements and exhibits
AI summary, unreviewedPharmaCyte Biotech Exchanges 851,304 Q/C Series G Warrants for 4,982,272 Unregistered Q/C Shares and Extends Q/C Series H Preferred Maturity
Material modification of security holders' rights · Amendments to articles or bylaws; fiscal year change · Other events · Financial statements and exhibits
AI summary, unreviewedPharmaCyte Biotech (PMCB) to Effect 1-for-19 Reverse Stock Split Effective November 12, 2026 to Regain Nasdaq Minimum Bid Price Compliance
Change in certifying accountant · Financial statements and exhibits
AI summary, unreviewedPharmaCyte Biotech dismisses CBIZ CPAs as auditor, engages Grassi & Co. amid disclosed material weaknesses in internal controls